Compare Medpace Holdings Inc (MEDP) vs Redwire Corporation (RDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Redwire Corporation — how do they compare? Medpace Holdings Inc trades at $601.45 (market cap $16.90B), while Redwire Corporation trades at $13.43 (market cap $3.38B). The key difference: Medpace Holdings Inc is far larger — about 5× Redwire Corporation's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Redwire Corporation nearer its low. Which is the better fit depends on your goals.
| MEDP | RDW | |
|---|---|---|
Market Cap | $16.90B | $3.38B |
Sector | Technology | Technology |
52-Week High | $620.59 | $25.90 |
52-Week Low | $393.42 | $5.06 |
Enterprise Value | $16.52B | $2.91B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $600.32, down 0.35% on the day, with a bullish technical signal supported by moving averages. The stock shows strong fundamentals with Q2 2026 earnings beating estimates at $4.25 per share versus $3.98 expected, and revenue growth projected from $2.53B in 2025 to $2.8B in 2026. Recent news highlights record bookings and raised guidance, though valuation ratios remain elevated with a P/E of 35.58 and P/B of 38.95.
Outlook remains positive driven by earnings momentum and strong backlog visibility, but risks include premium valuation compression and ongoing legal scrutiny. Analyst consensus is cautious with 73.7% hold ratings, though institutional interest persists with California State Teachers Retirement System increasing its position by 22.1% in Q1 2026.
Redwire (RDW) trades at $13.65, up 4.04% today, with strong technical momentum as moving averages signal bullish sentiment. The company reported record Q2 2026 revenue of $117.1 million and a growing $542.1 million backlog, though it continues to post significant net losses. Analyst consensus remains overwhelmingly positive with 80% buy ratings and a $17.50 price target, representing 28% upside potential from current levels.
While Redwire shows impressive revenue growth and defense contract momentum, investors face substantial risk from persistent losses, negative cash flow from operations, and high valuation multiples despite unprofitability. The company's pivot toward defense technology provides near-term stability but requires careful monitoring of margin improvement and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Redwire Corporation
Redwire Corporation is a pure-play space infrastructure company that provides a wide range of advanced solutions for the next generation of space exploration and utilization. The company's capabilities span critical space technology, including on-orbit servicing, satellite components, space robotics, and digital engineering. Redwire's products and services are used by civil, commercial, and national security customers to enable missions from low Earth orbit to deep space.
Read more on RDW →
